Estudio de factibilidad para el montaje de una empresa procesadora de subproductos par la industria de alimentos concentrados para animales.

La apertura de los mercados ha significado, a lo largo de estas últimas décadas, el anticiparse y prepararse ante los cambios, conocer y satisfacer plenamente las necesidades del consumidor y optimizar sustancialmente los sistemas productivos

Estudio de caso : vida empresarial / epidemiología empresarial. Caso de estudio - el éxito de el Pomar

Durante los años 1998 y 2002 El Pomar atravesó por una fuerte crisis económica caracterizada por una disminución de las ventas y falta de liquidez que conllevó a graves problemas con los proveedores. Igualmente, había deficiencia en la dirección del área administrativa y financiera generando debilidades frente a la competencia, pues carecían de controles en los procesos internos. Desde el año 2001 hasta el año 2003, las ventas de la empresa habían disminuido en un 65%, lo que ocasionó el cierre de 4 comercializadoras que tenían y el incumplimiento de sus obligaciones fiscales, financieras y con sus proveedores. Dada esta situación se le aconseja a la Junta Directiva tramitar un acuerdo de restructuración bajo la Ley 550 de 1999 con el fin de pagar a sus acreedores. Este acuerdo fue formalizado con los proveedores el 8 de noviembre de 2003 en donde todas las partes quedaron de acuerdo luego que la Superintendencia de Sociedades diera el aval para ejecutarlo. Para el año 2010 la empresa logró superar esta etapa, luego de que la administración se enfocó en reconquistar el mercado perdido, se vendió la empresa a accionistas colombianos para adquirir capital y se realizó de alianzas estratégicas con otras empresas. El presente trabajo tiene como tema central discutir el caso empresarial de cómo El Pomar logró resurgir de su crisis. De este modo, es cómo se establecerán los parámetros que determinarán el desarrollo del trabajo, tales como: perdurabilidad empresarial, ley 550 de 1999, resurgimiento y estrategia.

Operator, organizational, direct and general support : pumping assembly, flammable liquid, bulk transfer, 50 GPM, (Barnes model 9117CA) Army model SPE 16 FSN 4320-728-0265, (Barnes model 15671CA)[ Army model SPE 16A FSN 4320-658-2888, (Barnes model 4074CA) FSN 4320-271-1858.

"May 1968."

Lettre de M. l'abbé de ***, à un curé de ses amis, à l'occasion du serment civique décrété le 16 novembre dernier ([Reprod.])

Collection : Les archives de la Révolution française ; 8.658

Development of Quality Standards for Inclusion of High Recycled Asphalt Pavement Content in Asphalt Mixtures – Phase II, TR-658, 2015

To conserve natural resources and energy, the amount of recycled asphalt pavement has been steadily increasing in the construction of asphalt pavements. The objective of this study is to develop quality standards for inclusion of high RAP content. To determine if the higher percentage of RAP materials can be used on Iowa’s state highways, three test sections with target amounts of RAP materials of 30%, 35% and 40% by weight were constructed on Highway 6 in Iowa City. To meet Superpave mix design requirements for mixtures with high RAP contents, it was necessary to fractionate the RAP materials. Three test sections with actual RAP materials of 30.0%, 35.5% and 39.2% by weight were constructed and the average field densities from the cores were measured as 95.3%, 94.0%, and 94.3%, respectively. Field mixtures were compacted in the laboratory to evaluate moisture sensitivity using a Hamburg Wheel Tracking Device. After 20,000 passes, rut depths were less than 3mm for mixtures obtained from three test sections. The binder was extracted from the field mixtures from each test section and tested to identify the effects of RAP materials on the performance grade of the virgin binder. Based on Dynamic Shear Rheometer and Bending Beam Rheometer tests, the virgin binders (PG 64-28) from test sections with 30.0%, 35.5% and 39.2% RAP materials were stiffened to PG 76-22, PG 76-16, and PG 82-16, respectively. The Semi-Circular Bending (SCB) test was performed on laboratory compacted field mixtures with RAP amounts of 30.0%, 35.5% and 39.2% at two different temperatures of -18 and -30 °C. As the test temperature decreased, the fracture energy decreased and the stiffness increased. As the RAP amount increased, the stiffness increased and the fracture energy decreased. Finally, a condition survey of the test sections was conducted to evaluate their short-term pavement performance and the reflective transverse cracking did not increase as RAP amount was increased from 30.0% to 39.2%.

Post Hoc Analysis Of The Patricia Randomized Trial Of The Efficacy Of Human Papillomavirus Type 16 (hpv-16)/hpv-18 As04-adjuvanted Vaccine Against Incident And Persistent Infection With Nonvaccine Oncogenic Hpv Types Using An Alternative Multiplex Type-specific Pcr Assay For Hpv Dna.

The efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with HPV in the Papilloma Trial against Cancer in Young Adults (PATRICIA) was evaluated using a combination of the broad-spectrum L1-based SPF10 PCR-DNA enzyme immunoassay (DEIA)/line probe assay (LiPA25) system with type-specific PCRs for HPV-16 and -18. Broad-spectrum PCR assays may underestimate the presence of HPV genotypes present at relatively low concentrations in multiple infections, due to competition between genotypes. Therefore, samples were retrospectively reanalyzed using a testing algorithm incorporating the SPF10 PCR-DEIA/LiPA25 plus a novel E6-based multiplex type-specific PCR and reverse hybridization assay (MPTS12 RHA), which permits detection of a panel of nine oncogenic HPV genotypes (types 16, 18, 31, 33, 35, 45, 52, 58, and 59). For the vaccine against HPV types 16 and 18, there was no major impact on estimates of vaccine efficacy (VE) for incident or 6-month or 12-month persistent infections when the MPTS12 RHA was included in the testing algorithm versus estimates with the protocol-specified algorithm. However, the alternative testing algorithm showed greater sensitivity than the protocol-specified algorithm for detection of some nonvaccine oncogenic HPV types. More cases were gained in the control group than in the vaccine group, leading to higher point estimates of VE for 6-month and 12-month persistent infections for the nonvaccine oncogenic types included in the MPTS12 RHA assay (types 31, 33, 35, 45, 52, 58, and 59). This post hoc analysis indicates that the per-protocol testing algorithm used in PATRICIA underestimated the VE against some nonvaccine oncogenic HPV types and that the choice of the HPV DNA testing methodology is important for the evaluation of VE in clinical trials. (This study has been registered at ClinicalTrials.gov under registration no. NCT00122681.).